Skip to Main Content
Table 1—

Clinical characteristics of the 15 patients with MODY3 participating in the study

PatientSexAge (years)FPG (mmol/l)*A1C (%)BMI (kg/m2)Fat mass (%)Systolic BP (mmHg)*Diastolic BP (mmHg)*Antihyperglycemic medication
23.9 4.3/4.0/4.3 5.4 25.0 34 130 81 None 
44.9 7.0/8.4/7.4 6.6 22.4 32 109 70 None 
30.8 10.8/−8.6/11.3 8.1 22.6 30 110 82 Meal-time regular insulin 
34.2 7.0/6.2/6.8 6.4 21.9 17 115 77 Acarbose 25 mg twice a day 
42.5 12.2/11.3/13.5 8.7 24.3 21 118 86 Glimepiride 2 mg once daily 
50.6 11.3/10.3/−8.8 9.1 23.4 31 104 71 Glibenclamide 4 35 mg/day 
41.1 5.3/6.4/6.1 6.7 28.2 36 121 81 None 
62.6 5.2/4.4/4.8 6.5 24.7 34 144 83 Glimepiride 1 mg once daily 
32.9 7.5/7.3/8.5 7.8 22.3 15 136 78 None 
10 46.5 7.9/7.8/8.1 23.9 22 166 106 None 
11 66.1 16.2/15.5/14.2 9.9 23.4 23 165 88 Glibenclamide 35 mg/day 
12 40.2 8.3/8.4/7.8 5.9 16.7 16 113 69 Acarbose 50 mg × 3 
13 47.3 9.4/8.0/7.3 6.1 19.8 18 123 70 Acarbose 50 mg × 3 
14 20.0 5.4/7.3/5.8 23.1 28 112 67 Glimepiride 1 mg once daily 
15 28.0 5.0/6.5/7.6 6.7 21.2 25 125 70 None 
Median (interquartile range)  41.0 (16.5) 7.9 (3.9) 6.7 (2.3) 23.1 (2.4) 25 (14) 121 (24) 78 (13)  
PatientSexAge (years)FPG (mmol/l)*A1C (%)BMI (kg/m2)Fat mass (%)Systolic BP (mmHg)*Diastolic BP (mmHg)*Antihyperglycemic medication
23.9 4.3/4.0/4.3 5.4 25.0 34 130 81 None 
44.9 7.0/8.4/7.4 6.6 22.4 32 109 70 None 
30.8 10.8/−8.6/11.3 8.1 22.6 30 110 82 Meal-time regular insulin 
34.2 7.0/6.2/6.8 6.4 21.9 17 115 77 Acarbose 25 mg twice a day 
42.5 12.2/11.3/13.5 8.7 24.3 21 118 86 Glimepiride 2 mg once daily 
50.6 11.3/10.3/−8.8 9.1 23.4 31 104 71 Glibenclamide 4 35 mg/day 
41.1 5.3/6.4/6.1 6.7 28.2 36 121 81 None 
62.6 5.2/4.4/4.8 6.5 24.7 34 144 83 Glimepiride 1 mg once daily 
32.9 7.5/7.3/8.5 7.8 22.3 15 136 78 None 
10 46.5 7.9/7.8/8.1 23.9 22 166 106 None 
11 66.1 16.2/15.5/14.2 9.9 23.4 23 165 88 Glibenclamide 35 mg/day 
12 40.2 8.3/8.4/7.8 5.9 16.7 16 113 69 Acarbose 50 mg × 3 
13 47.3 9.4/8.0/7.3 6.1 19.8 18 123 70 Acarbose 50 mg × 3 
14 20.0 5.4/7.3/5.8 23.1 28 112 67 Glimepiride 1 mg once daily 
15 28.0 5.0/6.5/7.6 6.7 21.2 25 125 70 None 
Median (interquartile range)  41.0 (16.5) 7.9 (3.9) 6.7 (2.3) 23.1 (2.4) 25 (14) 121 (24) 78 (13)  
*

FPG is shown for each visit (ordered: nateglinide/glibenclamide/placebo, although the patients received the three drugs in random order).

Medication for coronary heart disease including β-blockers.

Antihypertensive medication. BP, blood pressure.

Close Modal

or Create an Account

Close Modal
Close Modal